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Abstract
Cancer biomarkers are emerging as important tools for disease diagnosis, prediction and 
prognosis. A significant number of studies have been reported in the field of biomarker 
discovery due to their potential as personalized targeted therapy. With the converging 
gap about their utilization as specific targets, studies have focused on identifying disease-
specific biomarkers in different cancer types. This chapter provides a comprehensive 
overview about different cancer-associated biomarkers, their prevalence in different can-
cer types and their use as targeted therapy. Additionally, we provide an in-sight on the 
therapeutic and diagnostic potential of different noncoding RNAs as cancer biomarkers.
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1. Introduction
Cancer is a genetic disease with great molecular diversity and unpredictable nature, which 
makes it complicated to generate reliable therapeutic interventions for treating cancer. Current 
treatment strategies include chemotherapy, radiotherapy and surgery. Cancer patients often 
show primary resistance to directed therapy or often develop adaptive resistance during the 
course of treatment. Hence it is extremely important to understand the molecular basis of cancer 
and search reliable biomarkers that can be employed in field of cancer diagnosis and treatment.
Precision medicine, classified as personalized cancer therapy, has increased our knowledge of 
aberrantly regulated genes and their involvement in tumorigenic pathways towards develop-
ing better therapeutic strategies. The advancement in information about the cause and effect 
of cancer genetics has translated to personalized targeted therapy, one such based on cancer 
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biomarkers. A biomarker is defined as biological molecule such as a protein, DNA, RNA or 
circulating extracellular vesicles (EVs) that can be found in blood, biological fluids and tissues 
and is an indicator of a normal physiologic or a diseased state. Cancer biomarkers are predic-
tive of altered gene signature marks at the transcription level and/or of abnormal proteomic 
or metabolomic patterns. These biomarkers are used for molecular diagnosis, patient progno-
sis and to determine the outcome of the targeted therapy. Hence, it is extremely important to 
understand the evolving landscape of cancer genetics and to combine tumor aberrations with 
personalized biomarker-based targeted therapy.
Human genome sequencing has identified approximately 30,000–40,000 genes and only 2–3% 
of the coding sequence of the genome are evolutionary conserved among mammals [1, 2]. 
About 98% of genome sequence was initially classified as junk DNA, but recent progress in 
deep sequencing has discovered these to be transcribed as noncoding RNAs (ncRNAs). These 
ncRNAs are grouped as different types of functional RNAs, such as Piwi-interacting RNA 
(piRNA), microRNA (miRNA), small nucleolar RNA (snoRNA), circular RNA (circRNA) and 
long noncoding RNA (lncRNA). ncRNAs have been shown to affect gene expression and 
disease progression, making them important targets for drug discovery. Clinically, aberra-
tions in ncRNAs show high prognostic and diagnostic importance. With the advancement 
in technology and enhancement in understanding the nature of ncRNAs, novel therapeutic 
treatments against cancer can be developed.
This chapter focuses on deciphering a comprehensive approach on the recent biomarkers that 
are available as therapeutic options, their scope, utility and implementation as prognostic 
and diagnostic tools for cancer therapy. We will focus on role of ncRNAs and discuss their 
potential use as a prognostic and diagnostic marker in various cancers. We will also address 
the challenges and possible solutions in their assessment as biomarker for therapeutic use.
2. Cancer biomarkers
A biomarker is a collection of genetic and proteomic signatures used to distinguish between 
healthy and diseased individual. These signatures can be in the form of DNA (ssDNA, dsDNA 
and retrotransposons), RNA (mRNA, miRNA, circRNA and lncRNA) or protein (antibodies 
and peptides) depending upon the site of secretion and isolation [3]. A biomarker is predic-
tive of disease prognosis and prediction, risk of recurrence or to determine the therapeutic 
potential of an identified target. The success of biomarker-based therapy can be attributed to 
the development of new sequencing strategies and characterization of tumor pathways with 
increasing knowledge about druggable targets and its predictive outcome. One of the earliest 
biomarkers to reach clinical practice was the identification of mutations in KRAS gene in case 
of metastatic colorectal cancer (CRC), which was predictive of therapeutic response towards 
anti-epidermal growth factor receptor (EGFR) [4]. However, owing to the heterogeneity of 
tumor cells, lack of information on specific biomarkers associated with particular disease type 
(and subtype) and different developmental strategies, biomarker-based therapy has not fully 
transcended to clinical stages.
Cancer biomarkers are broadly categorized into three divisions based on the specific signa-
ture it is associated with: diagnostic, predictive and prognostic biomarkers [5]. As the name 
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suggests, diagnostics biomarkers predict disease outcome associated with a particular malig-
nancy; predictive biomarkers predict the success of a particular therapeutic strategy applied to 
treat the disease followed by prognostic biomarkers that predict the risk of disease recurrence 
in the future. Currently, there are only a handful of FDA approved biomarkers in the market 
highlighting the present-day challenges, starting from their diagnosis to clinical approval. 
Some examples of FDA approved biomarkers include: HER2 overexpression as a predictive 
marker to determine the survival status of breast cancer patients treated with anti-HER2 ther-
apy [6]. Another example of FDA approved diagnostic maker include testing the patients sus-
pected with prostate cancer for the prostate-specific antigen (PSA) to test for malignancy of the 
associated disease (recent studies have found PSA screening to be inconsistent [7] however, 
further studies needs to be done to understand the discrepancy). Measurement of 70-gene 
expression analysis used to predict the recurrence of breast cancer after chemotherapy, is an 
FDA approved prognostic biomarker-based assay [8]. Apart from the FDA approved biomark-
ers, there are various new approaches being utilized towards personalized targeted therapy so 
as to bridge the gap between disease diagnosis and its clinical manifestation.
This section will discuss different types of biomarkers characterized thus far in different can-
cers; their scope and utility for targeted therapy and will provide an overview of the new 
biomarkers being identified and their possible translational to clinical levels (Figure 1).
2.1. Extracellular vesicles as biomarkers of cancer
Tumor cells are characterized by a neoplastic set of population that continuously divides and 
evolves into sub-population of cells, each with its own heterogeneity. Among the many rea-
sons for cancer therapeutics failure, one of them is the associated tumor heterogeneity and 
despite the new sequencing strategies developed, there are major challenges that need to be 
Figure 1. Different cancer-associated biomarkers. An overview of the different biomarkers associated with specific 
cancer types. Targeting these biomarkers could serve as important therapeutic option for associated malignancies 
(abbreviations as used in the text).
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overcome. Studies have found that tumor cells secrete EVs such as exosomes and macroves-
icles into the extracellular environment at a threefold higher rate than normal cells [9, 10]. 
These vesicles carry important genetic information such as DNA and RNA or protein frag-
ments that act as signatures of the secretory cell type [11]. Identification of EVs from patient’s 
blood stream, urine or plasma provide important insights into the cells they originate from, 
their genetic constituent and molecular variants. Identification of EVs as potential biomark-
ers along with the advancement in techniques for their successful isolation has enabled new 
therapeutic targets for cancer treatment. EVs are isolated from the conditioned media of cells 
in vitro or from biological fluids such as serum and plasma of patients. Some of the important 
identified secretory signatures in patient-derived vesicles known so far include receptor of a 
hepatocyte growth factor (HGF) identified in melanoma called MET [12], miRNAs in ovarian 
cancer [13] and in breast cancer the human epidermal growth factor receptor 2 (HER2/neu) 
[14] among many. EVs affect the cell milieu by enabling transfer and exchange of important 
information among different cell types, pre-metastatic niche formation and triggering cell 
type specific inflammatory immune response [15].
EVs are sub-classified into exosomes, macrovesicles and large oncosomes based on their size. 
Of these, exosomes (30–120 nm in diameter) are widely considered a valuable source of bio-
markers [16] and as important mediators of biological information. Exosomes are bilayered 
membranous structures comprising of various lipids and proteins, are formed from intra-
cellular vesicles and release their content extracellularly (outside the cell) [17]. Cancer cells 
secreted exosomes affect the microenvironment not only of the proximally located cells, but 
also cells of distal origin [18]. Information carried by exosomes not only plays significant role 
in normal pathological processes, but are also a hallmark of aberrantly regulated pathways in 
different cell type-associated malignancy. Exosomes have also been characterized as ‘liquid 
biopsy’ tools [19] owing to their stability in secreted bodily fluids such as plasma, urine or 
saliva. Various exosomal markers such as CD63, TSG101 and Alix, among many are known 
and their detection from conditioned media of cancer cells or from patient-derived tumor 
samples gives an indication of diseased process [20]. These specific protein markers allow for 
their characterization as specific liquid biopsy tools in cancers of different origin.
2.1.1. Exosomal proteins as cancer biomarkers
Various studies have reported that secretory information from exosomes could serve as a 
diagnostic tool in identification of breast cancer types. For example, in secretory exosomes 
of some breast cancer cell lines, which overexpressed HER2, full-length HER2 protein levels 
were found to be overexpressed when compared to normal cells [14]. It was found that in EGF 
(a ligand for HER2)-treated cells, the release of exosomes was higher as measured by the cell-
conditioned media and could serve as an important predictive tool in HER2-driven tumors. 
Monitoring the status of HER2 in blood-derived patient exosomes could therefore serve as a 
diagnostic tool in breast cancer and to improve the disease outcome. Another study found 
that a blood clotting specific protein called tissue factor (TF) correlated to increased tumor 
invasiveness in breast cancer by its incorporation into tumor-derived EVs [21]. TF-derived EVs 
from highly metastatic triple negative cell line MDA-MB-231 was transferred to less aggres-
sive MCF-7 cell line. It was observed that increased levels of incorporated TF associated with 
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more aggressive phenotype was responsible for cancer-associated thrombosis. Circulating 
exosomal vesicles are known to be upregulated during cancer progression and are associated 
with intercellular communication. A study found that breast cancer-derived exosomes from 
MDA-MB-231 (MDA-231) and MCF7 cells had elevated levels of transcription factor nuclear 
factor-κB (NF-κB) and its associated activation of signaling pathway in the macrophages as 
compared to exosomes from MCF10A cells. Increased NF-κB signaling led to increased pro-
duction of pro-inflammatory cytokines, which included factors such as interleukin-6 (IL6), 
granulocyte-colony stimulating factor (GCSF), chemokine ligand 2 (CCL2) and tumor necrosis 
factor α (TNFα) [22]. The increased inflammatory response in the macrophages contributed to 
metastatic niche formation and to modulate immune cells activity. Thus, targeting the activity 
of NF-κB pathway could be used as a therapeutic option to block the secretion of exosomes 
and consequently the formation of metastatic microenvironment. EVs from brain metastatic 
cells were found to be within 100 nm diameter size and expressing markers such as CD63 and 
CD9, characteristic of exosomes [23]. A study found that breast cancer-derived exosomes con-
tribute to the breakdown blood-brain barrier (BBB) and in vivo cell metastasis in the brain [23]. 
Secretion of exosomes was inhibited by targeting the degradation of EV proteins involved in 
its biogenesis such as neutral sphingomyelinase (nSMase2) and RAB27B. It was found that 
cells showed reduced migratory potential and that its migratory ability was restored when 
exosomes derived from breast cancer cells was added. Thus, targeting the cancer-derived 
exosomes could be an important therapeutic option for the prevention of BBB breakdown and 
to prevent its associated malignancies.
In another study, exosomes were isolated from the plasma of the patients with tumor grade 
I–IV [12]. It was found that patients with high exosomal proteins in stage IV had low sur-
vival rate as compared to patients in the same stage with low exosomal proteins content. 
Along with this, increased levels of specific melanoma protein, tyrosinase-related protein-2 
(TYRP2) [24] was seen in exosomes isolated from melanoma cell lines. Levels of TYRP2 in 
exosomes of patients also correlated to their increased metastatic progression of tumors. 
Given the increasing studies on exosomal horizontal transfer of molecules [25] and intercel-
lular communication, it was hypothesized that an oncogenic protein known to be metastatic 
could play a role. Among the different known proto-oncogenes such as MET, CD44, Annexin 
A6 and Hsp70 [26, 27], MET was considered a possible target owing to its role in invasion 
and metastasis [28]. It was found that in melanoma cell-derived exosomes, secretory vesicles 
could horizontally transfer MET to bone marrow-derived cells and that the levels of MET and 
phospho-MET (p-MET) protein was eventually found to increase in exosomes of these cells. 
Subsequently, MET and p-MET levels was also found to be high in circulating exosomes iso-
lated from patients with stages III and IV grade melanoma. Hence, it was hypothesized that 
targeting MET protein using specific inhibitors could provide new opportunities to restrict 
the metastatic progression of cells in tumors. A similar study on exosomes isolated from hepa-
tocellular carcinoma (HCC) cell lines showed MET proto-oncogene isolated from metastatic 
HCC cell line to increase the migratory potential of non-motile HCC cells [29]. The uptake 
of exosomes harboring MET protein in the cells triggered PI3K/AKT and MAPK signaling 
pathways [30] leading to increased metastatic potential of cells. Increased MET and p-MET 
along with increased p-AKT and MEK1/2 phosphorylation as well as levels of MMP2 and 
MMP9 were confirmed in the conditioned media of immortalized HCC cells after exosome 
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treatment from metastatic cells. Data were correlated with that obtained from HCC patients, 
where aberrant activation of MET/HGF pathway signaling pathway corresponded to poor 
prognosis and survival [31].
2.1.2. Exosomal nucleic acids as cancer biomarkers
First evidence of exosomal shuttle RNA (esRNA) came from a study which found that 
exosomes harbor both mRNA and miRNA and that they are involved in intercellular 
communication [11]. It was found that mRNA and miRNA secreted from mast cells were 
packed into exosomes and the coding information on mRNA could be translated into 
protein. The exosomes containing translatable information could be transferred between 
cell types, thus providing important insights and complexity in which the information is 
relayed. Targeting the exosomal RNA, that is shuttled between the cells, could therefore 
allow for targeted therapies in cell type-associated cancer. Subsequently, it was found that 
in ovarian cancer patients, levels of eight specific miRNAs obtained from exosomes were 
similar to that obtained cellularly. These circulating exosomal miRNAs isolated from serum 
samples include miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and 
miR-214 [13]. This suggests the importance of profiling circulating miRNAs from diseased 
patients and their use as important diagnostic tools and as liquid biopsy markers. A similar 
study based on identification of miRNA levels, found different miRNAs in the EVs isolated 
from the plasma of the patients infected with HBV or HCV infection. Expression profile 
of miRNAs isolated from circulating vesicles showed reduced miR-192, miR-200b, miR-92a 
and miR-150a levels [32]. Thus, miRNAs expression levels can be correlated to early stage 
liver fibrosis identification. Lipid bilayered vesicular contents of exosomes are recognized 
by multiple pathogen recognition receptors (PRRs), which include retinoic acid-inducible 
gene I (RIG-I) and toll-like receptors (TLRs) – TLR2, and TLR4 among others [22]. A study 
found that tumor-derived exosomes stimulated the activation of TLR3 in alveolar epithelial 
cells followed by the production of pro-inflammatory cytokines and pre-metastatic niche 
formation [33]. Since TLR3 recognizes dsRNA, RNA isolated from tumor-derived exosomes 
upregulated the expression of TLR3, thereby leading to cytokine production by activation of 
downstream NF-κB and MAPK pathways [34]. Activated TLR3 also led to the recruitment 
of neutrophils in the lungs, which elicited a pro-metastatic inflammatory response. Thus, 
insights into tumor-derived exosomal RNAs could provide important clues to target tumor 
metastasis in the lungs.
The first evidence of Exo-circRNA (circular RNA from exosomes) came from a study which 
showed them to be enriched at a twofold higher rate in liver cancer cells as compared to cir-
cRNA present in those cells [35]. Data from RNA-seq showed abundant circRNA in liver can-
cer cells as compared to normal cells. It was found that levels of these identified circRNA were 
about sixfold higher than linear RNA in the exosomes of these cells. The researchers further 
investigated whether serum from cancer affected patients were enriched with circRNA. Serum 
from patients with colon cancer showed high levels of an exo-circRNA, circKLD-HC10 in 
the exosomes of patients in comparison to healthy controls. This was the first evidence of 
exosome-based circular biomarkers as potential therapeutic options. In another study based 
on circRNA, expression profile of circRNAs present in both cells and exosomes of different 
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CRC cell lines that differ in the KRAS mutation status were analyzed [36]. KRAS is a proto-
oncogene first identified in Kirsten rat sarcoma virus [37] and whose mutation or upregula-
tion is associated with cancer progression based on the different pathways it acts upon. It was 
found that in cells where KRAS was mutated, a number of circRNA isolated from exosomes 
were downregulated as compared to those identified in cells having wild-type KRAS allele. 
These circRNAs include circFAT1 and circARHGAP5. To further investigate the reason for 
their downregulation, levels of known regulators of circRNA, adenosine deaminases acting 
on RNA (ADAR, an RNA editing enzyme) [38] and quaking (QK1, an RNA binding pro-
tein) [39] were determined. It was found that decreased levels of above-mentioned circRNAs 
directly correlated to decreased levels for QK1 found in the mutant cells. Levels of circRNAs 
could therefore serve as important biomarker for disease prediction.
The first report of tumor-derived exosomal DNA (exoDNA) showed that exosomes carried 
double-stranded DNA (dsDNA). The levels of these exoDNA corresponded to the mutational 
status of cancer cells and can therefore be used as an important circulating biomarkers in case 
of cancer-associated metastasis [40]. Mutation status of different genes known to be mutated 
in cancer cell lines were determined to see if the status of the genes corresponded to that 
obtained from exoDNA. It was found that BRAF allele was mutated in exoDNA in primary 
human melanoma cells containing BARF mutation as compared to cells that did not harbor 
the mutation. Also, status of EGFR, which is known to be mutated in case of non-small cell 
lung cancer (NSCLC) [41], was determined and same observation as compared to BRAF allele 
was found, confirming that exoDNA shows the same mutation status as that in parental cells. 
This shows that, exoDNA reflects the genomic status of the DNA present in cancer cells and 
because it is stable and feasible to isolate, could serve as an important biomarker. In addi-
tion to the dsDNA found in exoDNA, another study found the presence of ssDNA in the 
microvesicles (another subclass of extracellular vesicles with 30 nm–1 μm in diameter) from 
the tumor cells in culture in addition to retrotransposon elements [42]. Nucleic acids were 
identified from microvesicles released by cells in vitro and from tumors. It was found that 
along with RNA, ssDNA in the form of exoDNA as well as transposable elements were pres-
ent in the microvesicles. Levels of exo-RNA were found to be higher in medulloblastoma 
(MB) cells, which released more microvesicles as compared to normal cells with intact 18S and 
28S ribosomal peaks. Similarly, in MB cells levels of exoDNA was found to be more abundant 
as that in normal cells and was found to be single stranded. The strand status was confirmed 
using a detection chip that detected only dsDNA (the isolated single-stranded exoDNA was 
subjected to second strand synthesis, which converted it into double-stranded form and 
hence was detected by the chip). Retrotransposons such as human endogenous retroviruses 
(HERVs), long interspersed nuclear element-1 (LINE-1) and Alu were found to be enriched in 
microvesicles isolated from glioblastoma (GBM) cells. RNA from these transposable elements 
were enriched as compared to their cellular levels in these cells. Interestingly, experimental 
observations also suggested that HERV RNA is elevated in endothelial cells when these were 
exposed to microvesicles from tumor cells, indicating that these retrotransposons (jumping 
genes) could lead to genomic instability. Taken together, this study reveals that the uniquely 
identified retrotransposons RNA could serve as important biomarkers in tumor cells along 
with DNA from patient-derived body fluids. Additionally, the level of these retrotransposons 
could be an important indicator of the cell type-specific tumor origin [43].
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2.2. Inflammatory cytokines and chemokines as biomarkers of cancer
Levels of invading microbial pathogens during an inflammatory response are regulated by the 
first line of immune defense called the innate immune system [44]. The pathogen- associated 
molecular patterns (PAMPs) are bound by the associated PRRs, each recognizing its own 
unique set of patterns [45]. Upon receptor activation, a pro-inflammatory and antimicrobial 
response is triggered in the host system, which includes a series of signaling events compris-
ing of small molecules, transcription factors and kinases [46]. Subsequently, the signaling 
pathways relay the signal activating the associated cytokines or chemokines of the pathway 
[45], which generate a long-term response, ultimately leading to the activation of adaptive 
arm of the immune response.
Cytokines and chemokines are key modulators of inflammation and are involved in a variety 
of diseased processes based on their specific role. These can be pro- or anti-inflammatory, 
depending upon their class and type. For example, certain pro-inflammatory cytokines 
include interleukins (IL) such as IL-1, IL-6, TNFα and interferons (IFNs) among many [47]. 
Examples of anti-inflammatory factors include IL-12 and IL-10 among many [47]. Chemokines 
are small group of proteins characterized by conserved cysteine residues that recruit leuko-
cytes to the site of inflammation. Common chemokines include any protein with a CCL or 
CXC motif such as RANTES (CCL5) and IL8 (CXCL8) among many [47]. The level of cyto-
kines and chemokines differ greatly among individuals depending upon normal or diseased 
outcome. The downstream effects produced by these inflammatory regulators depend on the 
signaling pathway activated, their targets and the associated patterns. Although these fac-
tors are involved in many disease-associated processes, their levels are not consistent across 
similar diseased processes. The variation is due to the difference in their cut-off levels on what 
is considered normal versus abnormal [48] as well as the population size of the cohort used 
in the study (healthy or diseased) [49]. Hence, it is difficult to characterize them as unique 
biomarkers or as diagnostic tools for any cytokine-associated specific disease. Despite these 
limitations, considerable progress has been made and recent studies have focused on impor-
tant cytokines and chemokines, their involvement in cancer-associated diseases and their use 
as cancer biomarkers.
2.2.1. IL8 as a cancer-associated biomarker
IL8, a 6–8 kDa pro-inflammatory chemokine is the most widely studied for its role in recruit-
ing neutrophils to the site of infection, activation of angiogenesis and metastasis [47]. Many 
metastatic and tumors of breast, prostate and colon cancer are known to constitutively express 
IL8 [50]. IL8 ligand is bound and recognized by its G-protein coupled receptors (GPCRs) 
CXCR1 and CXCR2, with CXCR1 being the more specific receptor for mediating the response 
[47]. A number of therapeutic strategies therefore utilize the difference in pharmacological 
properties of these receptors to target and attenuate the effect of IL8 on the tumor microenvi-
ronment. High serum levels of IL8 correspond to poor prognosis and increased metastasis as 
seen in patients with metastatic breast cancer [51]. It was also noted that in cells treated with 
cytotoxic agents, IL8 levels were high with increased chemo-resistance observed in tumor 
cells. Another study on breast cancer found the role of a protein of Drosophila gene called 
dachshund (dac) to be important in patient prognosis [52]. Drosophila dac gene is involved in 
differentiation [53] and is a founding member of the human homolog dac protein DACH1, a 
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cell fate determination factor [54]. Levels of DACH1 directly correlated to patient survival 
and were found to be low in metastatic breast cancer. It was found that DACH1 inhibited 
cell migration and invasion by decreasing the levels of IL8 in breast cancer cells. DACH1 
repressed the IL8 promoter in a dose-dependent manner by occupying the AP-1 and NF-κB 
sites. Adding neutralizing antibody against IL8 resulted in a decrease in the migratory poten-
tial of the cells, showing that targeting IL8 as a biomarker could be a potential mechanism to 
inhibit cell growth.
In addition to binding to its own receptor, IL8 binds and upregulates the expression of another 
receptor, CXCR7 in case of prostate cancer leading to cell proliferation and growth [55]. It 
was observed that CXCR7-mediated growth was dependent on the activation of EGFR and 
independent of its own ligand, highlighting the importance of targeting CXCR7 as a potential 
biomarker along with IL8 in case of prostate cancer. In case of lung cancer, a study found 
that high circulating levels of IL8 were predictive of the risk of lung cancer in patients prior 
to diagnosis [56]. Along with IL8, IL6 was also found to be predictive of the high risk of lung 
cancer but only in cases within 2 years of blood collection. However, highest associated risk of 
lung cancer was determined in patients with several years of smoking habit and showed high 
IL8 and C-reactive protein (CRP) levels. Thus, plasma levels of IL8 along with CRP could be 
a more robust predictor of lung cancer (several years before diagnosis) for tumor progression 
and relapse.
Promoter methylation is often characterized with aberrant transcriptional regulation and/
or tumor suppressor genes silencing [57]. It was found that in MDA-231 and MDA-MB-435 
(MDA-435), two highly metastatic breast cancer cell lines that produce high levels of IL8, two 
CpG sites were methylated 1.2 kb upstream of IL8 promoter. The observed methylation pat-
tern showed a positive correlation with IL8 expression, suggesting additional uncharacterized 
epigenetic control known so far [58]. Similar approach in CRC was taken and it was observed 
that IL8 promoter was hypomethylated in 64% of tissue samples [59]. Hypomethylation of the 
promoter led to high IL8 protein levels and associated metastasis, showing that high IL8 lev-
els along with hypomethylated IL8 promoter, could be a useful marker for disease progres-
sion. Despite the vast array of information on IL8 and its role in different cancer progression 
and metastasis, only handful inhibitors against it are used in preclinical studies and even few 
have reached clinical trials. Neutralizing antibodies against IL8, ABX and HuMax are being 
used to block the binding to IL8 to its receptor [60]. ABX has shown to reduce tumor growth 
in mice in case of bladder cancer [61] and reduction in metastasis and angiogenesis along with 
reduced tumor size in case of melanoma [62]. Reparixin, an inhibitor of IL8 receptor CXCR1/2 
is in clinical trials for the treatment of patients affected with HER2-negative breast cancer and 
patients with TNBC along with paclitaxel (an FDA approved microtubule-stabilizing drug for 
ovarian, breast and lung cancer treatment [63]).
2.2.2. Other inflammatory factors as cancer biomarkers
In a study on colorectal cancer patients (stages I–IV grade), levels of inflammatory factors 
were determined in the blood at the time of surgery [64]. It was found that CRC-specific 
mortality directly correlated to the plasma levels of various inflammatory factors. In particu-
lar, levels of IL-4, TNFα, CCL1, CX3CL1, CCL20 and CCL24 were upregulated in patients 
with CRC-specific mortality. Thus, high levels of these inflammatory cytokines, chemokines 
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and interleukins found in the plasma of affected individuals could be a diagnostic marker 
to determine disease outcome and prognosis. A study on acute myeloid leukemia (AML) 
reported a cohort of seven inflammatory molecules to be upregulated and predictive of AML 
diagnosis irrespective of the disease heterogeneity [65]. These molecules include Cathepsin 
D, Ferritin, Macrophage migration inhibitory factor (MIF), Galectin-3, HGF, myeloperoxidase 
(MPO) and IL8 suggesting that their plasma levels could be predictive of disease diagnosis. 
In accordance with the TCGA database, levels of two other novel inflammatory molecules 
TNF-related apoptosis-inducing ligand (TRAIL) and MIF were downregulated and upregu-
lated, respectively, in the plasma of patients. Levels of MIF correlated with that found in other 
cancer types such as prostate and breast and is known to activate PI3K/Akt pathway, leading 
to anti-apoptosis and survival [66]. Thus, along with the seven biomarkers for prognosis, MIF 
could serve as an important therapeutic target in AML.
Carbohydrate antigen (CA) 19-9, is the only FDA approved diagnostic marker for prostate 
cancer but its diagnosis is limited due to inaccurate sensitivity and specificity in different 
prostate cancer subtypes [67]. There is thus an ardent need for a personalized biomarker 
predictive of disease outcome. A study found the levels of macrophage inhibitory cytokine 
1 (MIC-1), a novel TGF-β superfamily cytokine [68] in patient serum affected with prostate 
cancer, to be differentially expressed in comparison to healthy cohorts [69]. The diagnostic 
sensitivity and specificity percentage of MIC-1 from a total pool of different prostate cancer 
patients were found to be low but improved significantly when both CA 19-9 and MIC-1 
were detected in patient serum [70], showing that these biomarkers together could be used 
as diagnostic tools in prostate cancer. Another example of the use of multiple biomarkers for 
patient prognosis and disease outcome in prostate cancer came from a study which identified 
three inflammatory factors in tissue samples of patients post prostatectomy [71]. Among the 
30 cytokines that were measured, the expression levels of CCL4, IL-15 and CX3CL1 were 
significant and were predictive of recurrence free survival 5, 3 and 1-year post surgery.
2.3. Noninvasive cancer biomarkers
Research on biomarkers and its clinical translation is still in its early phase despite the recent 
advances in the field. This is due to the complexity in identifying the specific biomarker, 
its sensitivity of prediction and the isolation method used. There is therefore a need for the 
development of a noninvasive, inexpensive and accessible biomarker to evaluate disease pro-
gression and for better diagnosis. Besides the use of bio-fluids such as saliva and urine for 
basic health assessment, they are being used to monitor disease progression and possible 
outcome. The progress in the usage of saliva as a diagnostic biomarker fluid can be attributed 
to its FDA approval in 2003 for detecting HIV infection. In case of HIV, levels of a microglobin 
B2M b2, an end product of increased cytokine production and a soluble tumor necrosis factor 
α-receptor 11 (sTNFαR11) was detected to be higher in saliva of HIV infected patients than 
in control [72]. Thus, specific kits were designed to measure the levels of these inflamma-
tory molecules from saliva to be predictive of HIV infection. A study showed the comparison 
between sensitivity and specificity of samples obtained from oral fluid and serum for the 
evaluation of different viral Hepatitis type. It was found that samples obtained from saliva 
showed almost 100% sensitivity and specificity for the immunoglobin (Ig) M of Hepatitis A 
virus (HAV), surface antigen of Hepatitis B virus (HBV) and antibody of Hepatitis C virus 
(HCV), confirming that oral sampling offers opportunities for efficient prognosis [73]. In 
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another study based on identification of salivary transcriptome factors in oral squamous cell 
carcinoma (OSCC), levels of different mRNA signatures were determined. Among the differ-
ent identified targets, seven genes were found to be significantly upregulated in the follow-
ing order: high-IL8, moderate-H3 histone family member 3A (H3F3A), S100 Calcium Binding 
Protein P (S100P), IL1B, dual specificity phosphatase 1 (DUSP1), low-spermidine/spermine 
N1-acetyl transferase (SAT) and Ornithine decarboxylase antizyme 1 (OAZ1) [74]. Each of 
the identified gene has a role in cancer-specific pathways and is often deregulated leading 
to diseased progression. Therefore, the combination of identified salivary biomarkers with 
sensitivity and specificity of around 90% could help in early diagnosis of oral cancer and 
could be explored for other cancer types as well.
A study analyzed the level of protein c-ErbB-2 or HER2/neu in patient saliva with/without breast 
cancer [75]. The oncogenic protein is considered a prognostic marker having been identified 
in the tissue biopsies of patients with malignant tumor. The results showed that c-ErbB-2 level 
identified from saliva was upregulated and could therefore be used in the diagnosis of patients 
and to monitor disease recurrence. In another study based on salivary proteomics technology, 
protein profiles of patients with generalized aggressive periodontitis (GAgP) were compared 
with that of controls and 11 proteins were found to be altered [76]. Thus, salivary diagnostics 
identifying peptides and salivary proteins could play a significant role in understanding the 
cause of associated disease. In case of lung cancer, a study identified the methylation status 
of promoters of different TSGs in sputum of lung cancer patients. Promoters of genes such as 
O6-methylguanine DNA methyltransferase (MGMT), RAS association domain-containing pro-
tein 1(RASSF1A), death-associated protein kinase (DAPK) and B cell lineage-specific activator 
protein (PAX5a or BSAP) were highly methylated in patients who had survived lung cancer 
(these patients had a 6% recurrence risk) [77]. A similar study on head and neck squamous cell 
carcinoma (HNSCC) found promoters of similar TSGs to be hypermethylated and therefore 
important for the diagnosis in saliva of patients. These include RASSF1a, p16 INK4A, DAPKI 
and MGMT, confirming that these biomarkers play an important role and that methylation 
status of gene promoters is associated with increased cancer risk [78].
Other than saliva, another noninvasive accessible biomarker that can be used for disease diag-
nosis and prevention is urine. A study identified the methylation status of different TSGs in 
patients suffering from bladder cancer and found it to correlate with tumor grade. The TSGs 
identified were cyclin D2 (CCND2), Secretoglobin Family 3A Member 1 (SCGB3A1), BCL2 
Interacting Protein 3 (BNIP3), DNA-binding protein inhibitor ID-4 (ID4) and Runt-related tran-
scription factor 3 (RUNX3) [79]. Another study on pediatric tumors identified two biomarkers 
tissue inhibitor of metalloproteinases-3 (TIMP3) and basic fibroblast growth factor (bFGF) to 
be involved in detection of juvenile pilocytic astrocytomas (JPAs) in the brain [80]. The expres-
sion of biomarkers correlated to tumor grade and their levels decreased after treatment.
3. Overview of noncoding RNAs
Noncoding RNA (ncRNA) is RNA transcript that do not encode for the protein. In term of 
their sizes ncRNAs on threshold of 200 nucleotides length, are categorized in two types, small 
noncoding RNAs and long noncoding RNAs (lncRNAs). Small noncoding RNAs are sub 
categorized into microRNAs (miRNAs), small nucleolar RNAs (snoRNAs) and piwiRNAs 
Biomarker-Based Targeted Therapeutics
http://dx.doi.org/10.5772/intechopen.78377
169
(piRNAs) [81]. On the basis of their location with respect to protein coding genes, lncRNAs 
are categorized into: intergenic lncRNAs (present between two protein coding genes), intronic 
lncRNAs (introns of protein coding genes transcribe them), overlapping lncRNAs (a cod-
ing gene is located on the intron), antisense lncRNAs (the opposite strand of protein coding 
gene transcribe them) and processed lncRNAs (lacks an open reading frame ORF) [82]. These 
ncRNAs play an important role in different biological processes and are often deregulated in 
cancer. In this section, we will discuss ncRNAs as a potential biomarker, providing rationales 
for the development of therapeutics targeted against or based on these ncRNAs.
3.1. miRNA
miRNAs are universally present in plants and mammals and are single-stranded RNA of 
18–25 nucleotides in length. They regulate gene expression mainly at the posttranscriptional 
level in a sequence specific manner either by translational repression or by cleavage of their 
target mRNAs. Lin-4 and let-7 were identified in C. elegans as the first miRNAs. They were 
involved in nematode development. As many as 1881 precursors, 2588 mature; 495 precursors, 
765 mature and 1193 precursors, 1915 mature microRNAs have been interpreted in the human, 
rat and mouse, respectively, till date and this collectively has been cataloged in the miRNA 
Registry (http://microrna.sanger.ac.uk, V 21 July, 2014) [83]. Approximately one-third of the 
protein coding genes are believed to be controlled by miRNAs. These are first transcribed as 
pri-miRNA of more than 150 nucleotide (nt) long and then the stem loop is processed by an 
exonuclease Drosha in the nucleus, which results in pre-miRNA of 70 nt intermediate. These 
duplex pre-miRNAs are then exported to cytoplasm by Exportin-5 and Ran-GTP. They are then 
processed by Dicer to form mature miRNA of 22–29 nucleotide in length. Then they become 
part of RNA induced silencing complex (RISC), where one strand is cleaved (depending on 
the stability of 5’end) and the other remaining one functions as mature strand. Then this strand 
depending on the complementarity of the target mRNAs inhibits the translational initiation. 
miRNAs are expressed in different cells and at different stages, thereby play a crucial role in 
the regulation of various biological processes in various stages. They have been involved in 
several diseases like cancer [84]. Urgency for early cancer diagnosis and differentiating mul-
tiple cancer types is guiding the way for identifying miRNA signatures and monitor disease.
3.1.1. Techniques for miRNA quantification
Various methods have been developed by researchers to identify miRNAs in body fluids and 
tumors. Northern blotting is quantitative technique, which is used to detect RNA, but lacks 
sensitivity [85]. Researchers have used quantitative polymerase chain reaction (q-PCR) based 
on stem loop primers, that can differentiate between miRNAs isomers. Like whole genome 
array, miRNA microarray is used to differentiate deregulated miRNAs. Recently high 
throughput sequencing techniques have undergone a number of developmental changes and 
small RNA sequencing has been used to identify the novel miRNAs.
3.1.2. Benefits of using miRNA as biomarkers
miRNAs are deregulated frequently in several diseases and are specific to the tissues but 
some of them are highly conserved in different species and secreted in body fluids thereby 
serving as potential candidates for biomarkers. In comparison to large and extensive mRNA 
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expression signatures and identifying unknown tumor origin, miRNA signatures have shown 
more predictive power.
3.2. miRNAs as biomarker in different cancers
3.2.1. Lung cancer
Lung cancer is one of the major causes of cancer-related deaths in both men and women. Lung 
cancer is extremely difficult to detect in its early stages and the most prevalent is NSCLC [86]. 
The effectiveness of NSCLC treatment is expected to be improved through the implementa-
tion of robust and specific biomarkers. Novel targeted therapies are being developed based 
on molecular characteristics. Junichi et al. provided the first evidence of miRNAs role in lung 
cancer. Let-7 is reduced in human lung cancer and this alteration may have a prognostic impact 
in lung cancer patients who are surgically treated [87]. Global profiling studies have been done 
to identify the relationship between alterations of miRNAs and patient outcome. Deregulation 
of miR-155 and miR-let-7a-2 correlated with poor survival. Univariate analysis as well as multi-
variate analysis for hsa-mir-155 predicted poor survival [88]. In another global profiling study, 
investigators identified a set of five microRNAs to construct a signature by the risk score method. 
They have shown two microRNAs (hsa-miR-221 and hsa-let-7a) to be protective, and the other 
group (hsa-miR-137, hsa-miR-372 and hsa-miR-182∗) to be predictive of disease progression [89]. 
Similar genome-wide miRNA expression in patients with NSCLC (plasma samples) was per-
formed and a signature of 24 circulating miRNAs was identified. This study was done by pro-
filing 754 miRNAs in 100 NSCLC patients, showing a strong and highly predictive miRNA 
signature [86]. Another study done in TRAIL-resistant NSCLC shows miR-221 and miR-222 
expression to be elevated, which is necessary to maintain TRAIL-resistant phenotype, thus mak-
ing them as potential therapeutics or diagnostic tools [90]. Gasparini et al. profiled NSCLCs and 
showed that the NSCLCs can be classified into as rearranged ALK, mutated EGFR or mutated 
KRAS versus wild type based on miR-1253, miR-504 and miR-26a-5p expression levels [91].
3.2.2. Prostate cancer
Prostate cancer accounts for almost 15% of all new cancers in men. Several studies have linked 
circulating miRNAs expression to serve as accurate biomarkers for prostate cancer diagnosis. 
Singh et al. profiled expression of miRNAs in serum of prostate cancer patients that underwent 
radical prostatectomy. They identified a panel of 43 miRNAs that could help in differentiation 
of disease stages in 14 prostate cell lines and patient samples and correlated the expression 
of miR-222 and miR-125b as prognostic marker in these patients [92]. Another group identi-
fied miR-205 and miR-214, which were downregulated in prostate cancer and predicted it as 
potential biomarker in prostate cancer [93]. Circulating miRNAs that are most deregulated in 
men with high risk prostate cancer, metastatic and castrate-resistant prostate cancer (CRPC) 
includes miR-21, miR-141 and miR-221 [94, 95]. These data suggest the diagnostic importance 
of less invasive biological fluids as sources of biomarkers than blood or tissue of prostate cancer.
Many miRNAs (miR-155, miR-31, miR-152 and miR-137) host genes promoters that are asso-
ciated with CpG island, recent studies have shown these to be hypermethylated in prostate 
cancer [96]. They have shown the upregulation of KDM5B, a lysine-specific demethylase, to 
be associated with the methylated status of the host gene promoter of miR-137 and miR-155. 
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These methylated miRNAs host genes are promising diagnostic and/or prognostic biomark-
ers of prostate cancer. miR-193b has been implicated in prostate cancer with high sensitivity 
and specificity, whereas high miR-129-2 and miR-34b/c methylation levels are prognostic 
markers for disease-free survival [97]. Jacob Fredsøe et al. developed a novel urine-based 
three-miRNA prognostic model (miR-125b-5p*, let-7a-5p/miR-151a-5p) for prediction of bio-
chemical resource after radical prostatectomy in prostate cancer [98]. miR-125b, let-7a and 
miR-151a inhibit apoptosis, reduce proliferation and promote cell migration and invasion of 
prostate cancer cells, respectively, suggesting that these miRNAs could play a functional role 
in prostate cancer progression [98].
3.2.3. Triple negative breast cancer
Triple negative breast cancer (TNBC) treatment is difficult and it accounts for 20% of all breast 
cancers in women. Researchers are developing markers to detect breast cancer at early stage, 
which can lead to better disease outcome and prolonged patient survival. miRNAs have been 
shown to play a regulatory role in cell cycle progression, apoptosis, epithelial-mesenchymal 
transition, angiogenesis and drug resistance in breast cancer [99]. miR-125b, miR-145, miR-
21 and miR-155 were deregulated in a genome-wide miRNA expression profile study. This 
deregulation correlated with the expression of estrogen and progesterone receptor, stage 
of tumor and vascular invasion which demonstrate the existence of breast cancer-specific 
miRNA signatures [100]. In a recent study, researchers identified five miRNA signature 
(miR-92a-3p, miR-342-3p, miR-16, miR-21 and miR-199a-5p) to investigate the role of plasma 
miRNAs in TNBC, using a microarray platform. These five miRNA signatures are associated 
with increased risk of breast cancer [101]. Our group has shown miR-22 to regulate metastasis 
in breast cancer by downregulating TIP60, an acetyl lysine transferase and miR-22 and TIP60 
levels could be used as a prognostic marker for breast cancer [102].
3.2.4. Ovarian cancer
miRNA deregulation is prominent feature in ovarian cancer, thereby playing an important 
role in regulation of ovarian physiology. miR-125b, miR-29b, miR-29a and let-7 are down-
regulated in epithelial ovarian cancers (EOC) and are highly expressed in normal ovarian 
tissues. Researchers in this study have linked this deregulation of miRNA during normal 
ovarian functioning to EOC pathogenesis. High grade serous EOC with BRCA1/2 mutations 
or loss have high miR-29a and miR-29b expression [103]. In tumor tissues, 39 miRNAs are sig-
nificantly deregulated in comparison to normal ovary, of which miR-200a, miR-141, miR-200c 
and miR200b were most significantly overexpressed whereas miR-199a, miR-140, miR-145 
and miR-125b1 were most downregulated [104]. Eight miRNAs (miR-25, miR-506, miR-29c, 
miR-182, miR-128, miR-101, miR-141 and miR-200a) that were downregulated were predicted 
to regulate majority of miRNA-associated genes, which suggests the importance of miRNA 
networks as predictors of EOC survival [105].
3.2.5. Gastric cancer
Gastric cancer (GC) is one of the deadliest cancers in the world. Presence of sensitive and spe-
cific biomarkers for early detection and monitoring the progression of GC could lead to the 
reduction of mortality. Chun et al. used antisense miR-221 and miR-222 in SGC7901 cells and 
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showed that these miRNAs regulate radio sensitivity, cell growth and invasion by directly 
modulating PTEN expression in these cells [106]. Their study suggested inhibiting miR-221 
and miR-222 might be a novel therapeutic strategy for human GC. Another group showed 
miR-18a, which is a component of miR-17-92 cluster, to be overexpressed in GC tissue [107]. 
They found that the cell line overexpressing miR-18a showed increase in cell number and con-
centration of miR-18a in cultured medium, suggesting that miRNA might be released from 
cancer cells into the surrounding environment. They then concluded circulating miR-18a to 
be a useful biomarker for screening and monitoring tumor dynamics in GC [107].
Wang et al. did meta-analysis in 107 studies published in 42 articles and identified circulat-
ing miRNAs, miR-203, miR-146b-5p, miR-192 and miR-200c. They used bivariate model to 
calculate the sensitivity and specificity and used to plot the area under the summary receiver 
operator characteristic curve (AUC). The AUC is interpreted as the probability to correctly 
distinguish patients from normal controls. Using these parameters, they showed miR-203, 
miR-146b-5p, miR-192 and miR-200c has sensitivity of 0.75, a specificity of 0.81 and an AUC of 
0.85, showing good diagnostic performance in gastrointestinal cancers [108]. They concluded 
based on this study that circulating miRNAs specially a cluster of miRNA may present as 
promising biomarkers for the diagnosis of GC.
3.2.6. Pancreatic cancer
In digestive system, pancreatic cancer is the most aggressive cancer and worldwide it is a seri-
ous health problem. There is lack of prognostic and diagnostic marker due to which the over-
all survival of pancreatic cancer is poor. To search for effective biomarker in pancreatic cancer, 
miRNAs have been investigated in pancreatic tumor tissue, blood samples, pancreatic juice, 
stool and urine [109]. The miRNAs, miR-143, miR-223 and miR-30e showed increased levels 
in urine of stage 1 pancreatic ductal adenocarcinoma in comparison to healthy individuals. 
The combinational use of miR-143 and miR30e showed a sensitivity of 83.3% and a specificity 
of 96.2% in PDAC [110]. Another group showed miR-21 and miR-155 upregulation in PDAC 
and this deregulation is detected early in intraductal papillary mucinous neoplasm (IPMN), 
which suggests that these miRNAs can be considered as markers of transformation [111].
Li et al. identified another miRNA, miR-1290 in the serum of PDAC patients by q-PCR using 
TaqMan microRNA arrays [112]. In tumor tissue, it is overexpressed and shows prognostic 
significance. It also showed a higher diagnostic accuracy than CA19-9 in their cohort (AUC 
0.86 vs. 0.77 in the group PDAC vs. healthy controls). Another group showed five miRNAs 
including miR-10b, miR-155, miR-106b, miR-30c and miR-212 in plasma and bile, had excel-
lent accuracy, sensitivity and specificity for detection of PDAC over the control [113].
3.2.7. Hepatocellular cancer
In HCC, miR-15b,miR-21, miR-130b and miR-183 showed upregulation in HCC tissue as com-
pared to adjacent non-tumor tissue [114]. These miRNAs were detected in serum and cell cul-
ture medium but showed decreased levels after surgical resection. They also showed miR-15b 
and miR-130 could be used to distinguish HCC from healthy samples with high sensitivity 
and specificity. Kourtidis et al. showed miR-30b overexpression restores the abnormal cell 
growth in liver cancer cell lines. The abnormal cell growth reversed, on restoring miR-30b lev-
els [115]. The miRNAs have been shown to have a great potential as a biomarker for HCC but 
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till date there is no consensus on detection or good miRNA sets, for example, there is a better 
response to interferon therapy on miR-26 downregulation but this is associated with poor 
survival [116]. A summary of miRNAs involved in different cancers is presented in Table 1.
3.3. Long-noncoding RNA
Long noncoding RNAs (lncRNAs) are the RNA transcript that do not encode for proteins 
and do not have open reading frame. lncRNAs are transcribed by RNA polymerase II and 
controlled by the transcriptional activators of the SWI/SNF complex. lncRNA transcripts are 
usually spliced, capped and polyadenylated, similar to mRNAs. lncRNAs represent a het-
erogeneous group of ncRNAs and they are usually expressed in tissue and cellular context, 
and are localized in the both nucleus and cytoplasm. The presence of secondary structures 
in lncRNA such as stem loops and hairpins, help them to interact with proteins and chroma-
tin and are important for various functions of lncRNAs. In general, lncRNAs act as guides 
to recruit proteins, scaffolds for grouping protein complexes, transcriptional enhancers by 
chromatin reorganization, decoys to release proteins from chromatin or antagonists for other 
regulatory ncRNAs, for example, miRNAs.
3.4. lncRNAs as biomarker in cancer
3.4.1. Breast cancer
Expression levels of lncRNAs have been investigated in breast cancer tissues compared to 
normal tissues indicating that some may be potential biomarkers for breast cancer diagnosis. 
lncRNA-BC2 and lncRNA-BC5 were upregulated and lncRNA-BC4 and lncRNA-BC8 were 
downregulated in breast cancer patient samples in a study done by Ding et al. [117]. In grade 
3 breast cancer, lncRNA-BC4 expression was significantly lower and lncRNA-BC5 expression 
was significantly higher. lncRNAs have been demonstrated to be easily detected in bodily 
fluids by multiple studies, such as lncRNA RP11-445H22.4 was found to be significantly 
increased in breast cancer patients serum with high sensitivity and specificity [118]. Zhao et al. 
identified a set of lncRNAs are deregulated in breast cancer patients and distinguish low-risk 
patients from high risk patients. Breast cancer patients with high expression of LINC00324 
and low expression of PTPRG antisense RNA 1 (PTPRG-AS1) and small nucleolar RNA host 
gene 17 (SNHG17) co-related with longer overall survival and tumor grade [119]. High SPRY4 
intronic transcript 1 (SPRY4-IT1) expression levels was increased in 48 breast cancer tissues in 
comparison to normal tissue and this upregulation was found to be associated with increased 
tumor size, poorer prognosis and disease-free survival (DFS) [120].
Hox transcript RNA (HOTAIR) is overexpressed in breast cancer tissue and increases the 
invasion and metastatic capacity. This increased expression is predictive of overall survival 
and progression-free survival [121, 122]. Metastasis-associated lung adenocarcinoma tran-
script 1’s (MALAT1) is upregulated in 26 pairs of estrogen receptor positive breast cancer 
patients. Further analysis of a larger group of breast cancer patients comprised of 204 samples 
and correlated high expression of MALAT1 with ER+ breast cancer patients [123]. In an analy-
sis of 151 breast cancer tissues, which comprised of stages 1–111 invasive ductal carcinoma, 
lncRNA BC040587 was found to be downregulated and this downregulation was correlated 
with differentiation of tumor and status of menopause [124]. LINC00472 is highly expressed 
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in non-metastatic breast cancer tissues and the high expression of LINC00472 was associ-
ated with Luminal A type of breast cancer. High expression of LINC00472 showed reduced 
risk of relapse and death in patients [125, 126]. Lei zhong et al. analyzed 600 breast cancer 
patients with ER+ status from the TCGA data and identified six lncRNAs (HAGLR, STK4-AS1, 
DLEU7-AS1, LINC00957, LINC01614 and ITPR1-AS1) gene signature as prognostic survival 
biomarkers [127].
3.4.2. Ovarian cancer
Guo et al. performed genome-wide miRNA and lncRNA expression profiles and catego-
rized ovarian cancer patients (BRCA1/2 wild-type) into high and low survival on the basis 
of LINC01234 and CCDC144NL-AS1 and two miRNAs (miR-637 and miR-129-5p) signatures 
[128]. Wang et al. identified seven lncRNAs such as XR_948297, XR_947831, XR_938728, 
XR_938392, NR_103801, NR_073113 and NR_036503, which were deregulated in most ovarian 
tumor samples and showed significant correlation with a poor chemotherapeutic response 
of EOC patients [129]. Rong Liu et al. identified signature lncRNAs such as ZFAS1, RP5-
1061H20.5, RP11-489O18.1, RP11-136I14.5, RP11-16E12.1, CTD-2555A7.3, LINC01514 and 
TUG1 to play a mechanistic role in chemotherapeutic resistance in HGS-OvCa tumors and act 
as diagnostic markers [130].
3.4.3. Leukemia
In AML patients, lncRNAs MEG3 are poorly expressed and overexpression of MEG3 inhibits 
AML cells proliferation, regulates cell cycle and promotes apoptosis [131]. Diaz-Beya et al. 
have reported that HOTAIRM1 is highly expressed in 215 intermediate-risk AML patients 
and this expression is associated with poor prognosis, overall survival and disease recur-
rence [132]. In AML patients with Nucleophosmin 1 (NPM1) mutation, a higher expression 
of HOTAIRM1 is associated with poor clinical outcome. Another study by De Calra et al. 
Cancer miRNAs Expression Clinical features Refs.
Breast miR-21, miR-155 Upregulated Plasma of patient with TNBC (n = 5) and 
non-TNBC (n = 5), as well as healthy 
controls
[100]
miR-10b, miR-125b, 
miR-145, miR-21
Downregulated
miR-145, miR-451 Downregulated Novel biomarkers for early detection [183]
let7a, miR-21,miR-141, 
miR-214
Upregulated
miR-92a-3p, 
miR-342-3p
Upregulated Expression is correlated with tumor stage 
and subtypes
[101]
miR-16, miR-21 and 
miR-199a-5p
Downregulated
miR-210 Upregulated Hypoxic environment in breast cancer [184]
miR-451 Upregulated Multidrug resistance in breast cancer [185]
miR-22 Upregulated Epithelial-mesenchymal transition, 
metastasis
[102]
miR-18a Upregulated Paclitaxel resistance [186]
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Cancer miRNAs Expression Clinical features Refs.
Gastric miR-433, miR-9 Downregulated Marker for the advanced gastric carcinoma [187]
miR-221, miR-222 Upregulated Regulate radio sensitivity, and cell growth 
and invasion by directly modulating PTEN 
expression
[106]
miR-203, miR-146b-5p, 
miR-192, miR-200c
Upregulated Diagnostic marker [108]
miR-214, miR-17, 
miR-20a, miR-200c, 
miR-107, miR-27a, 
miR-433, let-7 g, 
miR-125a-5p, miR-760, 
miR-206, miR-26a
Upregulated Poor prognosis in gastrointestinal cancer 
patients
[188]
miR-200b, miR-185 Downregulated
miR-125a, miR-137, 
miR-141, miR-146a,
miR-206, miR-218, 
miR-486-5p, miR-506
Downregulated Prognostic marker [189]
miR-451, miR-199a-3p, 
miR-195
Upregulated Poor prognosis for recurrence and survival [190]
let-7 g, miR-342, miR-
16, miR-1, miR-34
Upregulated Associated with chemosensitivity [191]
miR-18a Upregulated Increase in cell number and released in cell 
culture medium
[107]
Hepatocellular 
carcinoma
miR-15b, miR-21, 
miR-130b, miR-183
Upregulated High sensitivity and specificity in HCC 
patients
[192]
miR-16, miR-195, 
miR-199a
Upregulated HBV-associated HCC samples from 
healthy controls
[193]
miR-29a, miR-29c, 
miR-133a, miR-143, 
miR-145, miR-192, 
miR-505
Upregulated HBV-associated HCC from chronic HBV 
infection
[192]
miR-200c, miR-200, 
miR-21, miR-224, 
miR-224, miR-10b, 
miR-222
Upregulated HBV-related HCC compared to patients 
with chronic HBV
[194]
miR-517a, miR-520c Upregulated Downregulation of both miR-517a and 
miR-517c contribute to HCC development 
through Pyk2 regulation
[195]
miR-18a, miR-224, 
miR-199a*, miR-195, 
miR-199a, miR-200a, 
miR-125a
Upregulated Promotes tumor progression [196]
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Cancer miRNAs Expression Clinical features Refs.
Ovarian miR-125b, miR-29b, 
miR-29a, let-7
Downregulated Epithelial ovarian cancer pathogenesis [103]
miR-519a Upregulated Poor prognosis of patients with ovarian 
cancers
[197]
miR-25, miR- 506, 
miR-29c, miR-182, 
miR-128, miR-101, 
miR-141, miR-200a
Downregulated miRNA networks as predictors of epithelial 
ovarian cancer survival
[105]
let-7e, miR-30c, miR-
130a, miR-335
Upregulated Prognostic tool to monitor the 
chemotherapy outcome
[198]
miR- 125b Downregulated
miR-214, miR-199a*, 
miR-200a
Upregulated Cell survival and cisplatin resistance [199]
miR-100 Downregulated
mir-135b, miR-200a, 
miR-200b, miR-200c, 
miR-141, miR-429
Upregulated Prognostic and diagnostic marker [200]
miR-205, miR-449, 
miR-429
Upregulated Diagnostic marker in endometrioid ovarian 
cancer
[201]
miR-204, miR-99b, 
miR-193b
Downregulated
Lung miR-155 and miR-
let-7a-2, miR-145, 
miR-21
Upregulated Associated with adenocarcinoma patients 
survival
[88]
miR-221, miR-222 Upregulated Induce TRAIL resistance and enhance 
cellular migration
[90]
miR-1253, miR-504, 
miR-26a-5p
Upregulated Therapeutic target to overcome resistance 
to ALK inhibitors
[91]
miR-1343-3p miR-
671-3p, miR-103a-3p
Upregulated Deregulated in cancerous vs. normal lung 
tissue
[202]
let-7e, miR-342-3p Downregulated
miR-210, miR-182, 
miR-486-5p, miR-30a, 
miR-140-3p
Upregulated Poor survival in squamous carcinoma [203]
miR-31 Downregulated
let7g, miR-26 Downregulated Deregulated in squamous carcinoma vs. 
adenocarcinoma
[204]
miR-21 Upregulated Marker of tumor progression in 
adenocarcinoma
[205]
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have recently identified XLOC_109948 long noncoding RNA as a strong prognostic factor in 
NPM1-mutated patients [133]. An association study performed in a case-control cohort made 
up of 149 leukemia patients, including Philadelphia positive (Ph(+)) acute lymphoblastic 
leukemia (ALL) and AML samples, and 183 healthy controls. They found a single nucleo-
tide polymorphism mapping to CDKN2BAS encoding for ANRIL antisense noncoding RNA 
showed significant correlation with the ALL phenotype [134]. In neoplastic T lymphocytes 
samples from 21 children with ALL, T-ALL-R-lncR1 was expressed in 11 cases. T-ALL-R-
lncR1 might be associated with T-ALL, provide a new entry point for early diagnosis and 
targeted therapy for T-ALL [135]. In 68 chronic lymphocytic leukemia (CLL) patients, 62 mul-
tiple myeloma (MM) patients and 36 healthy controls, 5 lncRNAs (Taurine upregulated gene1 
(TUG1), lncRNA-p21, metastasis-associated lung adenocarcinoma transcript-1(MALAT1), 
HOTAIR and growth arrest-specific 5 (GAS5)) were identified, of which lncRNA-p21 showed 
low expression in CLL patients [136]. lncRNA-p21 forms a complex with hnRNPK ribonucleo 
Cancer miRNAs Expression Clinical features Refs.
Pancreatic miR-143, miR-223, 
miR-30e
Upregulated Overexpressed in patients with stage I 
cancer when compared with age-matched 
healthy individuals
[110]
miR-21, miR-155 Upregulated Expression was significantly correlated 
with tumor stage and poor prognosis
[111]
miR-20a, miR-21, miR-
24, miR-25, miR-99a, 
miR-185, miR-191
Upregulated Prognostic biomarker with high sensitivity 
and specificity
[206]
miR-10b, miR-155, 
miR-106b, miR-30c, 
miR-212
Upregulated Excellent accuracy, sensitivity and 
specificity for detection of PDAC over the 
control patients
[113]
Prostate miR-222, miR-125b Upregulated Prognostic marker in prostate cancer 
patients
Metastasis
[92]
miR-21, miR-221 Upregulated Analysis of miR-21, -141, and -221 in blood 
of PCa patients reveals different pattern of 
molecules in clinical subgroups of PCa
[94, 95]
miR-141 Downregulated
miR-155, miR-31, 
miR-152, miR-137
Upregulated Hypermethylated [96]
miR-1290, miR-375 Upregulated Decreased overall survival in Castration-
resistant prostate cancer (CRPC) patients
[207]
miR-375, miR-141 Upregulated Released into incubation medium from 
androgen-stimulated cells
[208]
miR-16, miR-
92a,miR-103, miR-
107,miR-197, miR-34b, 
miR-328, miR-485-3p, 
miR-486-5p, miR-92b, 
miR-574-3p, miR-636, 
miR-640, miR-766, 
miR-885-5p
Upregulated Upregulated in serum from prostate cancer 
patients compared to normal donor sera
[209]
miR-125b-5p*let-7a-5p/
miR-151a-5p
Upregulated Urine-based three-miRNA prognostic 
model for prediction of BCR
[98]
Table 1. Summary of various miRNAs involved in different cancers, their expression and clinical features.
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protein and suppresses cell cycle regulatory genes on stimulation by p53 [137]. lncRNA-p21 
could be developed as a biomarker for the disease or drug design. Miller et al. showed trans-
lation regulatory long noncoding RNA 1 (TRERNA1) is overexpressed in 144 CLL patients’ 
samples, act as enhancer and regulate expression of-SNAIL in cis-dependent manner [138]. 
They have also correlated the high expression of TRERNA1 with shorten treatment time. 
TRERNA1 expression resulted in decreased DNA damage and cell death in B-CLL cell line, 
suggesting TRERNA1 as a novel biomarker.
3.4.4. Lung cancer
lncRNAs have been successfully isolated from bronchial brushings, biopsies and sputum. 
Still only, few species of lncRNAs have been identified in biofluids; therefore, more sam-
pling methods are required. Recently, there have been progresses in discovery of lncRNA 
biomarkers in lung cancer. MALAT-1 emerged as most promising candidate NSCLC in tis-
sue specimens [139]. MALAT-1 is overexpressed and is a prognostic marker for metastasis 
and poor prognosis in cancer that arises from squamous cell carcinoma. In small cell lung 
cancer (SCLC) patients, CCAT2 was associated with shorter overall survival. High expression 
of CCAT2 was an independent unfavorable prognostic factor for SCLC patients as analyzed 
by univariate and multivariate analyses [140]. Qiu et al. showed CCAT2 is upregulated in 
NSCLC tissues in comparison with paired adjacent normal lung tissues and this overexpres-
sion is significant in lung adenocarcinoma but not in squamous cell carcinoma [141].
Zhang eb et al. have shown that the lncRNA TUG1 was downregulated in lung cancer tis-
sues and this correlates with advanced pathological stage, greater tumor size and shorter sur-
vival time in both lung squamous cell carcinoma and lung adenocarcinoma [142]. Sun et al. 
have demonstrated that the downregulation of SPRY4-IT1 correlated with larger tumor size, 
advanced pathological stage and lymph node metastasis in NSCLC patients and this reduced 
expression of SPRY4-IT1 with lymph node metastasis status may serve as a biomarker of late 
stage and poor survival [143].
3.4.5. Prostate cancer
Recently, a lot of progress has been made in identifying the lncRNAs as biomarker in pros-
tate cancer and the most recent one is the PCA-3 assay, which has been approved by the 
FDA. In prostate cancer, PCA3 was suggested as a urinary biomarker and detected using 
q-PCR in a cohort of 108 men [144]. One of the lncRNA extensively studied in prostate cancer 
pathogenesis is prostate cancer-associated intergenic noncoding RNA transcript 1 (PCAT1). 
In 102 prostate cancer tissues, PCAT1 was upregulated and correlated with disease progres-
sion [145]. Srikantan et al. found prostate cancer gene expression marker 1 (PCGEM1) to be 
upregulated in African-American men compared to Caucasian-American men and is associ-
ated to patients with high prostate cancer risk [146].
Schlap1 showed higher expression in metastatic prostate cancer and the expression of Schlap1 
correlated with metastasis and prostate cancer-specific mortality [147–149]. Another study 
did RNA sequencing and found prostate cancer-associated noncoding RNA transcript 18 
(PCAT-18) to be upregulated in prostate cancer in comparison to neoplasm. In prostate cancer 
cell lines, PCAT-18 inhibits cell invasion, migration and proliferation, which suggest it to be a 
therapeutic target and biomarker for prostate cancer [150]. Isin et al. analyzed exosomes from 
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the urinary samples from 30 prostate cancer patients and 49 benign prostatic hyperplasia 
(BPH) patients and found lncRNA-p21 to be deregulated, whereas another lncRNA GAS5 
expression was not changed [151]. This result suggested lncRNA-p21 as a biomarker for the 
prostate cancer detection. Ren et al. has demonstrated lncRNA FR0348383 to be differentially 
expressed and its expression levels could differentiate prostate cancer from BPH. Another 
group has reported same lncRNA as a novel biomarker in prostate cancer detection using 
post-digital rectal examination (post-DRE) urine of the patients [152].
3.4.6. Liver cancer
The lncRNA urothelial carcinoma-associated 1 (UCA1) is shown as a single lncRNA-based 
HCC diagnostic approach. In both studies, UCA1 performed better than Alpha-fetoprotein 
(AFP). In combination with JUN mRNA, UCA1 lncRNA showed 90% sensitivity and 80% 
specificity and in early stage HCC detection, the same combination showed 100% sensitivity 
and 80% specificity underlining the importance of RNA-based detection methods for early 
stage HCC diagnosis [153]. In 86 (35 female, 51 male) HCC patients, Liu et al. showed NEAT1 
to be overexpressed in HCC patients and this was an independent risk factor associated with 
the prognosis of patients [154]. Wang et al. analyzed TCGA data and shown the expression 
profiles of four lncRNAs (RP11-322E11.5, RP11-150O12.3, AC093609.1 and CTC-297N7.9) 
for 371 patients with HCC were significantly and independently associated with survival of 
HCC patients [155]. Several studies suggested circulating ncRNAs and tumor tissue-derived 
ncRNAs for HCC diagnosis or survival prediction [156, 157]. While tissue-derived ncRNAs 
might be functionally relevant in the tumor, they are not necessarily good biomarkers for 
diagnosis. To obtain a tissue sample, a liver biopsy is needed, which is an invasive proce-
dure with potential side effects. Therefore, the detection of circulating ncRNAs in body fluids 
instead of tumor tissue is advantageous for HCC diagnosis and surveillance. A summary of 
lncRNAs involved in different cancers is presented in Table 2.
3.5. Circular RNA
Circular RNA (circRNA) is a class of RNA that are abundant, evolutionary conserved and 
stable. They were identified 30 years ago as a result of an error in RNA splicing, but their func-
tion in different cellular processes is now being appreciated [158]. In acute lymphoblastic leu-
kemia (ALL) patients and cell lines, Salzman et al. discovered circRNAs by RNA sequencing 
[159]. After this discovery, many other circRNAs were identified, shown to be endogenously 
expressed as well as stable. Backsplicing of exons, introns or both results in the formation 
of exonic or intronic circRNAs [160]. RNA binding proteins act as activators or inhibitors in 
circRNA formation [39]. Conn et al. have shown that the RNA binding protein QK1 binds 
to the introns flanking a circRNA and forms a looped structure by dimerization promoting 
circularization [39]. circRNAs have been classified as noncoding RNA, but recently there have 
been reports suggesting that they may be translated to protein if there is a presence of internal 
ribosome entry site (IRES) [161–163]. Recently, circRNAs have been studied extensively in 
relation to human diseases, especially cancers. Here we will discuss the potential of circRNAs 
as potential biomarkers and as therapeutic targets. A summary of circRNAs involved in dif-
ferent cancers is presented in Figure 2.
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3.5.1. Gastric cancer
Lai et al. examined co-expression networks between circRNAs and mRNAs and found three 
candidate (circRNA0047905, circRNA0138960 and circRNA7690-15) oncogenes in gastric 
tissue. circRNA0047905 was predicted as biomarker in gastric tissue as it showed highest 
diagnostic accuracy [164]. Huang et al. analyzed plasma samples from patients with GC and 
healthy controls and showed hsa_circ_0000745 to be downregulated in GC tissue. Its expres-
sion correlated with tumor formation in gastric tissue, whereas in plasma, it correlated with 
tumor node metastasis (TNM) stage. Expression level of hsa_circ_0000745 in plasma in com-
bination with carcinoembryonic antigen (CEA) level is a promising diagnostic marker for GC 
[165]. In plasma and GC tissues, hsa_circ_002059 was shown to be upregulated in comparison 
to adjacent normal tissues and this deregulation was associated with metastasis, TNM, gen-
der and age. This suggests hsa_circ_002059 as a potential stable biomarker for the diagnosis of 
gastric carcinoma [166]. Another study showed upregulation of circPVT1 in GC tissue due to 
the amplification of its genomic locus. circPVT1 acts as a sponge for miR-125 family, promotes 
cell proliferation and also acts as a prognostic marker for disease-free survival and overall 
survival of GC patient [167].
Cancer lncRNAs Expression Clinical features Refs.
Breast lncRNA-BC2 and 
lncRNA-BC5
Upregulated Positively correlated with patients’ 
age, clinical stage, progesterone 
receptor (PR) concentration
[117]
lncRNA-BC4 and 
lincRNA-BC8
Downregulated Negatively correlated with PR 
concentration
LINC00324 Upregulated Expression pattern is associated 
with ER+ and ER- subtypes, tumor 
histology
[119]
PTPRG-AS1, SNHG17 Downregulated
SPRY4-IT1 Upregulated Prognostic biomarker and 
therapeutic candidate for breast 
cancer. Biomarker for overall 
survival and progression-free 
survival
[120]
HOTAIR Upregulated Potential tumor marker for breast 
cancer diagnosis
[121, 127]
MALAT1 Upregulated Poor prognosis and correlated 
with tumor differentiation
[123]
BC040587, neuroblastoma-
associated transcript 1 
(NBAT1) and eosinophil 
granule ontogeny transcript 
(EGOT)
Downregulated New marker of prognosis in breast 
cancer
[124]
LINC00472 Upregulated Prognostic and predictive value in 
the clinical management of breast 
cancer
[125, 126]
HAGLR, STK4-AS1, 
DLEU7-AS1, LINC00957, 
LINC01614 and ITPR1-AS1
Upregulated Prognostic biomarker of survival 
of breast cancer patients
[127]
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Cancer lncRNAs Expression Clinical features Refs.
Ovarian LINC01234 and 
CCDC144NL-AS1
Upregulated Overexpression is correlated with 
overall shorter survival
[128]
XR_948297, XR_947831, 
XR_938728, XR_938392, 
NR_103801, NR_073113 and 
NR_036503
Upregulated Correlated with a poor 
chemotherapeutic response of 
EOC patients
[129]
ZFAS1, RP5-1061H20.5, 
RP11-489O18.1, RP11-
136I14.5, RP11-16E12.1, 
CTD-2555A7.3, LINC01514 
and TUG1
Upregulated Play a mechanistic role in 
chemotherapeutic resistance in 
HGS-OvCa tumors
[130]
Leukemia MEG3 Downregulated Regulate cell cycle and promote 
apoptosis
[131]
HOTAIRM1 Upregulated Associated with poor prognosis, 
shorter overall survival and 
disease recurrence
[132]
XLOC_109948 Downregulated Strong prognostic factor in NPM1 
mutated patients
[133]
ANRIL Upregulated Significant correlation with the 
ALL phenotype
[134]
T-ALL-R-lncR1 Upregulated Early diagnosis and targeted 
therapy of T-ALL suppress cell 
cycle regulatory genes
[135]
TRERNA1 Upregulated Decreased DNA Damage and cell 
death in B-CLL cell line
[138]
Lung MALAT-1 Upregulated Predictive marker for metastasis 
development and poor prognosis 
in cancer arising from squamous 
cell carcinoma
[139]
CCAT2 Upregulated Promotes invasion of non-small 
cell lung cancer
[140, 141]
TUG1 Downregulated Correlated with advanced 
pathological stage, greater 
tumor size and shorter survival 
time in both lung squamous 
cell carcinoma and lung 
adenocarcinoma
[142]
SPRY4-IT1 Downregulated Correlated with larger tumor size, 
advanced pathological stage and 
lymph Node metastasis in NSCLC 
patients
[143]
Neoplasm182
3.5.2. Hepatocellular carcinoma
hsa_circ_0001649 expression is significantly downregulated in 89 HCC samples in compari-
son to adjacent liver tissue and this correlates with tumor embolus and size, indicating its use 
as a potential biomarker for HCC [168]. Fu et al. showed lower expression of hsa_circ_0004018 
is correlated with serum AFP level, tumor diameters, differentiation, Barcelona Clinic Liver 
Cancer stage and TNM in HCC [169]. Using a circRNA microarray, Huang et al. identified 226 
differentially expressed circRNAs, of which 189 were significantly upregulated and 37 were 
downregulated. circRNA_100,338, one of the upregulated circRNAs in HCC, is correlated with 
a low cumulative survival rate and metastatic progression in HCC patients with Hepatitis B 
[170]. Shang et al. performed circRNA microarray and found circ_0000520, circ_0005075 and 
circ_0066444 are deregulated in HCC. They found upregulation of only circ_0005075 to be 
associated with tumor size [171].
Cancer lncRNAs Expression Clinical features Refs.
Prostate PCA3 Upregulated Urinary biomarker [144]
PCAT1 Upregulated Implicated in prostate cancer 
progression
[145]
PCGEM1 Upregulated Associated to patients with high 
prostate cancer risk
[146]
Schlap1 Upregulated Prognostic biomarker [147–149, 210]
PCAT-18 Upregulated Inhibits cell invasion, migration 
and proliferation
[150]
lncRNA-p21 Downregulated Biomarker for the prostate cancer 
detection
[151]
FR0348383 Upregulated Novel biomarker in prostate 
cancer detection using post-DRE 
urine of the patients
[152]
Liver UCA1 Upregulated 90% sensitivity and 80% specificity 
in early stage HCC detection
[153]
NEAT1 Upregulated Associated with the prognosis of 
patients with HCC
[154]
RP11-322E11.5, RP11-
150O12.3, AC093609.1, 
CTC-297 N7.9
Downregulated Associated with prognosis of 
liver cancer, and could provide 
novel insights into the potential 
mechanisms of HCC progression
[155]
HULC and Linc00152 Upregulated Applied as a potential target for 
HCC treatment
[157]
Table 2. Summary of various lncRNAs involved in different cancers, their expression and clinical features.
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3.5.3. Colorectal cancer
In CRC, Wang et al. showed the expression of hsa_circ_001988 was decreased in tumor tis-
sues and the expression was correlated with differentiation and perineural invasion, sug-
gesting hsa_circ_001988 as a novel treatment target and a potential biomarker of CRC [172]. 
Zhang et al. performed circRNA array in paired tumor and adjacent non-tumorous tissues 
from six CRC patients and found lower expression of hsa_circRNA_103809 and hsa_cir-
cRNA_104700 in CRC tissues. The expression of hsa_circRNA_103809 was correlated with 
lymph node metastasis and tumor node metastasis stage, whereas expression level of hsa_
circRNA_104700 was significantly correlated with distal metastasis. hsa_circRNA_103809 
and hsa_circRNA_104700 are involved in the development of colorectal cancer and serve as 
potential biomarkers for the diagnosis of colorectal cancer. Another circRNA, cir-ITCH was 
downregulated in CRC and inhibits Wnt/β-catenin pathway by increasing ITCH expression 
suggesting a mechanistic role for circ-ITCH in CRC by regulating the Wnt/β-catenin pathway 
[173]. Studies cited above illustrate that circRNAs are promising biomarkers for CRC.
3.5.4. Laryngeal cancer
Till date not much study on circRNA profiling in laryngeal cancer have been done. Microarray 
analysis in four paired laryngeal squamous cell cancer (LSCC) tissues revealed 698 circRNAs 
to be altered. hsa_circRNA_100855 was most upregulated in LSCC when compared to adjacent 
non-neoplastic tissues [174]. This expression of hsa_circRNA_100855 correlated with tumor 
Figure 2. Circular RNAs in cancer. A list of the important circRNAs involved in different cancer types and their 
associated levels.
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grade, tumor stage, neck nodal metastasis and primary location of LSCC. CircRNA_100855 
plays an important role in the tumorigenesis of LSCC can be used as a prognostic and diag-
nostic biomarkers in LSCC.
3.5.5. Bladder cancer
In bladder carcinoma, circRNA expression was done using microarray assay by Zhong et al. 
and researchers demonstrated that circTCF25 is overexpressed in bladder cancer and this 
overexpression downregulate miR-103a-3p and miR-107, increase cyclin-dependent kinase 
6 (CDK6) expression and promote proliferation and migration in vitro and in vivo [175]. The 
data also suggested that circTCF25 might be a new biomarker for bladder cancer. In another 
study by the same group, they found that circRNA-MYLK and VEGFA were significantly 
upregulated and co-expressed in bladder cancer [176]. The expression of circRNA-MYLK co-
related with the progression of stage and grade of bladder cancer, suggesting that circRNA-
MYLK would be a promising target for bladder diagnosis and therapy.
3.5.6. circRNAs in other cancers
In cutaneous squamous cell carcinoma (cSCC), 322 circRNAs were identified to be deregu-
lated and having 1603 miRNA response elements (MREs) [177]. These deregulated circRNA 
were shown to be involved in tumor formation by acting as a sponge for miRNAs. Another 
study identified circRNA expression signatures in PDAC by microarray platform [178]. They 
have shown that initiation and progression of PDAC is controlled by circRNAs. Li et al. found 
that circ-ITCH expression is downregulated in esophageal squamous cell carcinoma (ESCC) 
compared to the peritumoral tissue. circ-ITCH act as a sponge for miR-7, miR-17 and miR-214, 
thereby increasing the level of ITCH and promoting ubiquitination and degradation of phos-
phorylated Dvl2, thereby inhibiting the Wnt/β-catenin pathway [179]. circRNA CDR1as have 
70 selectively conserved target sites of miR-7, and lot of studies have shown that miR-7 can 
directly downregulate oncogenes [180]. This miRNA regulation by CDR1as has been shown 
to be involved in cancers such as breast cancer, melanoma, GC, gliocytoma, liver cancer and 
NSCLC.
3.6. Noncoding therapeutics in clinical trials
To date, the use of miRNA-based therapeutics in malignant disease is poorly explored. 
Presently, many companies are developing miRNA as therapeutic targets either by overex-
pressing tumor suppressor miRNA or by inhibiting oncogenic miRNAs. miR-122 has been 
shown to play an important role in HCC. Currently Santaris pharma has used locked nucleic 
acid-based antisense oligonucleotide against miR-122, thereby reducing the miR-122 lev-
els and playing a positive role in the regulation of Hepatitis C viral replication [181]. This 
antisense has already passed Phase II clinical trials and shows promising results in patients 
infected with HCV infection [182]. Mirna therapeutic has also developed a miR-34a mimic, for 
miR-34a overexpression and currently is under trials for primary liver cancer. They have also 
developed anti-miR-155, which has shown a promising result in restoring normal function 
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and reducing cell proliferation in hematological malignancies. Similarly, miR-34 liposomes 
are also under stage I clinical trial. Regulus therapeutics has introduced several anti-miR in 
preclinical trials, for example, in renal fibrosis the expression of miR-21 is high and anti-
miR-21 reduces the expression of extracellular matrix proteins. In atheroclosis, anti-miR-33 
has been used successfully to regulate cholesterol and fatty acid homeostasis by decreasing 
LDL triglycerides and increasing HDL. This anti-miR-33 has cleared the preclinical trials. In 
HCC, anti-miR-221 has been successful in delaying the tumor progression, thereby increas-
ing the survival rate. miRagen therapeutics have also developed anti-miR-92 (for peripheral 
artery disease) and anti-miR-15 (for myocardial infarction), which are in preclinical trials.
Besides the above examples of successful trials, there are still major obstacles that need to 
overcome for miRNA-based therapeutics. miRNAs have multiple targets, hence the off target 
effects need to be examined carefully. Similarly one gene can be regulated by multiple miR-
NAs that can compromise the effect of miRNA-based treatment. In addition, delivery mecha-
nism for miRNA that show high specificity and efficacy is lacking. Overall, miRNA-based 
therapeutics hold a promising future for personalized medicine based on miRNA biomarkers 
but for this, a first step towards better understanding of miRNA biology is required.
4. Conclusion
Recent advancement in techniques and the vast repertoire of information has made it feasible 
to identify and characterize different biomarkers. However, due to the constant evolving epi-
genetic landscape of cancer cells along with the heterogeneity in the cell population subtype, 
their translation into clinical stage offers various limitations. Additionally, population size 
used in the study as well as tumor samples used to identify the genes and pathways involved 
needs to be further validated. Samples handling methods need to be specified as variation 
might occur depending on the site of isolation as well as the method used to identify the spe-
cific biomarker type. Therefore, extensive research on various biomarker profiles is important 
to understand their potential as therapeutic and diagnostic tools in different cancer types. 
Integration of biomarker discovery with other techniques such as imaging (labeling) of the 
specified tumor target site can provide information about the disease end point and offer a 
noninvasive way to monitor dose requirement.
The use of advance sequencing technologies and bioinformatics approaches in studying the 
transcriptome of cancer has led to the identification of ncRNAs such as miRNAs, lncRNAs and 
circRNAs. These ncRNAs are deregulated in most of the cancers in comparison to the normal 
tissue, which suggests that they might play an important role in biological function of these 
cancers. miRNAs are the most extensively studied ncRNAs, but their potential as effective 
biomarkers is still in its nascent stage. A number of studies have been done to demonstrate the 
potential of miRNAs as biomarkers and as diagnostic tools, but challenges still remain. For 
example, a large dataset has to be used to successfully predict specfic miRNAs as biomarker 
for prognostic and diagnostics use. To ensure the accuracy of the diagnosis based on miR-
NAs, one has to identify all the targets of miRNAs, thus removing the false positive targets. 
New delivery mechanisms also need to be developed for specificity and efficacy. Similarly, 
the identification of lncRNAs as important regulators of cancers has potentiated their use as 
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promising tool for biomarkers. lncRNAs are stable in body fluids and their expression is spe-
cific to different pathological conditions. However, their development as biomarkers is still in 
its preliminary stage, proper normalization control and a large cohort has to be used to make 
the study reliable. Additionally, identification of new mutations, deletions and amplifications 
in the ncRNAs as well as genomic alterations affect their structure and function. circRNAs are 
known to be deregulated in cancers and although several studies have documented their role, 
many questions regarding their biogenesis and function is still unclear.
To summarize, this chapter highlights the different types of biomarkers that have been char-
acterized in different cancer types thus far, their mode of action and their targeting strate-
gies. The therapeutic potential of different biomarkers and their use in clinical trials has also 
been discussed. Despite the recent advancements, a comprehensive approach on biomarker 
biogenesis is required to integrate the available information and to translate them as tools of 
prognostic and diagnostic potential.
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